Biocept Inc.

4.36-0.0300-0.68%Vol 137.47K1Y Perf 3.87%
Apr 16th, 2021 16:00 DELAYED
BID4.36 ASK4.39
Open4.37 Previous Close4.39
Pre-Market- After-Market4.32
 - -  -0.04 -0.92%
Target Price
20.00 
Analyst Rating
Strong Buy 1.00
Potential %
358.72 
Finscreener Ranking
★★★★+     58.56
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★     46.53
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★+     51.72
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap58.43M 
Earnings Rating
Buy
Price Range Ratio 52W %
9.43 
Earnings Date
12th May 2021

Today's Price Range

4.254.41

52W Range

3.4613.00

5 Year PE Ratio Range

-0.3000-0.4000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.22%
1 Month
-27.45%
3 Months
-18.66%
6 Months
-7.23%
1 Year
3.87%
3 Years
-94.19%
5 Years
-99.62%
10 Years
-

TickerPriceChg.Chg.%
BIOC4.36-0.0300-0.68
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.30
2.60
0.32
0.52
-74.30
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
22.30
-217.60
-208.90
-454.50
-33.12
RevenueValueIndustryS&P 500US Markets
26.01M
1.94
85.33
75.35
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.14-
Q03 2020-0.48-0.4310.42
Q02 2020-0.40-0.50-25.00
Q01 2020--0.80-
Q04 2019--2.00-
Q03 2019--2.50-
Q02 2019--3.80-
Q01 2019--0.61-
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.372.63Positive
12/2020 QR-0.38-90.00Negative
12/2020 FY-0.397.14Positive
12/2021 FY-1.88-8.67Negative
Next Report Date12th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume137.47K
Shares Outstanding13.40M
Trades Count3.90K
Dollar Volume1.80M
Avg. Volume559.22K
Avg. Weekly Volume264.39K
Avg. Monthly Volume691.05K
Avg. Quarterly Volume575.27K

Biocept Inc. (NASDAQ: BIOC) stock closed at 4.36 per share at the end of the most recent trading day (a -0.68% change compared to the prior day closing price) with a volume of 139.58K shares and market capitalization of 58.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 95 people. Biocept Inc. CEO is Michael W. Nall.

The one-year performance of Biocept Inc. stock is 3.87%, while year-to-date (YTD) performance is -1.8%. BIOC stock has a five-year performance of -99.62%. Its 52-week range is between 3.46 and 13, which gives BIOC stock a 52-week price range ratio of 9.43%

Biocept Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 2.74, a price-to-sale (PS) ratio of 2.20, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.36%, a ROC of -145.84% and a ROE of -99.25%. The company’s profit margin is -33.12%, its EBITDA margin is -208.90%, and its revenue ttm is $26.01 Million , which makes it $1.94 revenue per share.

Of the last four earnings reports from Biocept Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biocept Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Biocept Inc. is Strong Buy (1), with a target price of $20, which is +358.72% compared to the current price. The earnings rating for Biocept Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biocept Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biocept Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.94, ATR14 : 0.50, CCI20 : -98.72, Chaikin Money Flow : -0.61, MACD : -0.56, Money Flow Index : 46.52, ROC : -17.74, RSI : 39.14, STOCH (14,3) : 5.99, STOCH RSI : 0.76, UO : 36.76, Williams %R : -94.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biocept Inc. in the last 12-months were: David F. Hale (Sold 2 320 shares of value $1 288 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Biocept Inc.

Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cells and circulating tumor DNA assays utilizing a standard blood sample. The company's lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.

CEO: Michael W. Nall

Telephone: +1 858 320-8200

Address: 5810 Nancy Ridge Drive, San Diego 92121, CA, US

Number of employees: 95

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

71%29%

Bearish Bullish

56%44%

Bearish Bullish

59%41%

News

Stocktwits